An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT ID: NCT04717414

Last Updated: 2025-07-10

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 313 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-25
• Study Completion Date: 2032-08-18

Brief Summary

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions.

The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period.

Following the Day 169 Response Assessment, subjects who did not show clinical benefit will have the option to unblind. Subjects who were on placebo during the Blinded Core Treatment Period will have the opportunity to crossover into the Open-Label Extension Treatment Period and receive Luspatercept.

Detailed Description

Permitted Concomitant Medications and Procedures

• Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their respective label and as prescribed as part of the subject's standard-of-care therapy as prescribed by their physician prior to study entry.
• Best supportive care (BSC) includes, but is not limited to, treatment with transfusions (eg, RBC, platelet, whole blood), ICTs, antibiotic, antiviral and/or antifungal therapy, and nutritional support as needed.
• Granulocyte colony-stimulating factors (ie, G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF]) are allowed only in cases of neutropenic fever or as clinically indicated per product label.
• Prophylactic antithrombotic therapy is permitted.
• Thrombopoietin and platelet transfusions are permitted.
• Treatment with systemic corticosteroids is permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone during the study.
• Administration of attenuated vaccines (eg, influenza vaccine) is allowed if clinically indicated per Investigator discretion.
• Iron chelation therapy (ICT) is to be used according to the product label. If the label permits, the ICT dose should be stable during at least the first 24 weeks of IP. Initiation of ICT while within the first 24 weeks of IP should be clinically indicated to treat an AE.

Prohibited Concomitant Medications

The following concomitant medications are specifically excluded during the course of study treatment:

• Cytotoxic, chemotherapeutic, targeted, or investigational agents/therapies (excluding JAK2 inhibitor therapy)
• Azacitidine, decitabine, or other hypomethylating agents
• Lenalidomide, thalidomide, and pomalidomide
• Erythropoietin stimulating agents (ESAs) and other RBC hematopoietic growth factors (eg, IL-3)
• Hydroxyurea or other alkylating agents
• Androgens (unless given to treat hypogonadism)
• Oral retinoids (topical retinoids are permitted)
• Arsenic trioxide
• Interferon
• Anagrelide
• Systemic corticosteroids at a dose equivalent to > 10 mg prednisone
• Investigational products for the treatment of MPN-associated MF

Conditions

Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Anemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Experimental Arm: Luspatercept (ACE-536)

Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)

Group Type: EXPERIMENTAL

ACE-536

Intervention Type: DRUG

Subcutaneous Injection

Control Arm: Placebo

Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Subcutaneous Injection

Interventions

ACE-536

Subcutaneous Injection

Intervention Type: DRUG

Placebo

Subcutaneous Injection

Intervention Type: OTHER

Other Intervention Names

Luspatercept; BMS-986346

Eligibility Criteria

Inclusion Criteria

• Subject is ≥18 years of age at the time of signing the ICF.

• Subject has a diagnosis of PMF according to the 2016 World Health Organization (WHO) criteria or diagnosis of post-ET or post-PV MF according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report.
• Subject is requiring RBC transfusions as defined as:.

i) Average RBC-transfusion frequency: 4 to 12 RBC units/12 weeks immediately up to randomization. There must be no interval > 6 weeks (42 days) without ≥ 1 RBC transfusion.

ii) RBC transfusions are scored in determining eligibility when given for treatment of:.

A. Symptomatic (ie, fatigue or shortness of breath) anemia with a pretransfusion Hgb ≤ 9.5 g/dL or.

B. Asymptomatic anemia with a pretransfusion Hgb ≤ 7 g/dL.

iii) RBC transfusions given for worsening of anemia due to bleeding or infections are not scored in determining eligibility.

• Subjects on continuous (eg, absent of dose interruptions lasting ≥ 2 consecutive weeks) JAK2 inhibitor therapy as approved in the country of the study site for the treatment for MPN-associated MF as part of their standard-of-care therapy for at least 32 weeks, on stable daily dose for at least 16 weeks immediately up to the date of randomization and anticipated to be on a stable daily dose of that JAK2 inhibitor for at least 24 weeks after randomization.

• Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2.
• A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP)participating in the study must:.

i) Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the subject practices true abstinence* from heterosexual contact.

ii) Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception** without interruption, 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy.

• Male subjects must: Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential** while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) following IP discontinuation, even if he has undergone a successful vasectomy.

i) True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.].

ii) Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Combined (estrogen and progestogen containing) hormonal contraception: Oral, Intravaginal, Transdermal; Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral, Injectable hormonal contraception, Implantable hormonal contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence.

• Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
• Subject is willing and able to adhere to the study visit schedule and other protocol requirements including the use of the electronic patient reported outcomes device.

Exclusion Criteria

• The presence of any of the following will exclude a subject from randomization:.
• Subject with anemia from cause other than MPN-associated MForJAK2 inhibitor therapy (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infection, or any type of known clinically significant bleeding or sequestration).
• Subject use of hydroxyurea, immunomodulatory compounds such as pomalidomide, thalidomide, ESAs, androgenic steroids or other drugs with potential effects on hematopoiesis ≤ 8 weeks immediately up to the date of randomization.

i) Systemic corticosteroids are permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone for the 4 weeks immediately up to randomization.

ii) Iron chelation therapy (ICT) is permitted providing the subject is receiving a stable dose for the 8 weeks immediately up to randomization.

• Subject with any of the following laboratory abnormalities at screening:.

i) Neutrophils: < 1 x 10^9/L.

ii) White blood count (WBC): > 100 x 10^9/L.

iii) Platelets: the lowest allowable level as approved for the concomitant JAK2 inhibitor but not < 25 x 10^9/L or > 1000 x 10^9/L.

iv) Peripheral blood myeloblasts:> 5%.

v) Estimated glomerular filtration rate:< 30 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease [MDRD] formula) or nephrotic subjects (eg, urine albumin-to-creatinine ratio > 3500 mg/g).

vi) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):> 3.0 x upper limit of normal (ULN).

vii) Direct bilirubin: ≥ 2 x ULN.

A. Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (eg, ineffective erythropoiesis).

• Subject with uncontrolled hypertension, defined as repeated elevations of systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, that is not resolved at the time of randomization.
• Subject with prior history of malignancies, other than disease under study, unless the subject has been free of the disease for ≥ 3 years. However, subject with the following history/concurrent conditions is allowed:.

i) Basal or squamous cell carcinoma of the skin.

ii) Carcinoma in situ of the cervix.

iii) Carcinoma in situ of the breast.

iv) Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system).

• Subject with prior hematopoietic cell transplant or subject anticipated to receive a hematopoietic cell transplant during the 24 weeks from the date of randomization. 7. Subject with stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months immediately up to the date of randomization.
• Subject with major surgery within 2 months up to the date of randomization. Subject must have completely recovered from any previous surgery immediately up to the date of randomization.
• Subject with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of ≥ 2 units of packed red cells) in the last 6 months prior to the date of randomization.
• Subject with inadequately controlled heart disease and/or have a known left ventricular ejection fraction < 35%.
• Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
• Subject with known human immunodeficiency virus (HIV), evidence of active Hepatitis B (HepB) as demonstrated by the presence of Hepatitis B surface antigen (HBsAg) and/or positive for Hepatitis B virus DNA (HBVDNA-positive), and/or evidence of active Hepatitis C (HepC) as demonstrated by a positive Hepatitis C virus RNA (HCV-RNA) test of sufficient sensitivity.
• Subject with prior therapy of luspatercept or sotatercept.
• Subject with history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product.
• Pregnant or breastfeeding females.
• Subject participation in any other clinical protocol or investigational trial that involves use of experimental therapy (including investigational agents) and/or therapeutic devices within 30 days or for investigational agents within five half-lives, whichever comes later, immediately up to the date of randomization.
• Subject with any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study or places the subject at unacceptable risk if he/she were to participate in the study. 18.Subject with any condition or concomitant medication that confounds the ability to interpret data from the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Local Institution - 110

Los Angeles, California, United States

Local Institution - 135

Orlando, Florida, United States

Local Institution - 133

Plantation, Florida, United States

Local Institution - 112

Chicago, Illinois, United States

Local Institution - 124

Lexington, Kentucky, United States

Local Institution - 114

Ann Arbor, Michigan, United States

Local Institution - 108

St Louis, Missouri, United States

John Theurer Cancer Center

Hackensack, New Jersey, United States

Mount Sinai Medical Center

New York, New York, United States

University of Pittsburg Medical Center

Pittsburgh, Pennsylvania, United States

Allegheny Health Network

Pittsburgh, Pennsylvania, United States

Local Institution - 130

Knoxville, Tennessee, United States

The University of Texas - MD Anderson Cancer Center

Houston, Texas, United States

Local Institution - 119

Salt Lake City, Utah, United States

Local Institution - 172

Ciudad Autónoma de BuenosAires, Buenos Aires, Argentina

Hospital Italiano de La Plata

La Plata, Buenos Aires, Argentina

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Monash Medical Centre

Clayton, Victoria, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia

Gosford Hospital

Gosford, , Australia

Royal Hobart Hospital

Hobart, , Australia

Local Institution - 272

Graz, , Austria

Krankenhaus der Elisabethinen Linz, I Interne Abteilung

Linz, , Austria

Local Institution - 271

Vienna, , Austria

Local Institution - 274

Vienna, , Austria

Local Institution - 318

Bruges, , Belgium

Local Institution - 312

Brussels, , Belgium

Local Institution - 313

Hasselt, , Belgium

Uz Leuven

Leuven, , Belgium

Local Institution - 319

Liège, , Belgium

Local Institution - 316

Roeselare, , Belgium

Local Institution - 315

Verviers, , Belgium

Cliniques Universitaires UCL de Mont-Godine

Yvoir, , Belgium

Local Institution - 181

Calgary, Alberta, Canada

Local Institution - 179

Edmonton, Alberta, Canada

Local Institution - 183

Vancouver, British Columbia, Canada

University Hospital - London Health Sciences Centre

London, Ontario, Canada

Local Institution - 180

Toronto, Ontario, Canada

Local Institution - 177

Montreal, Quebec, Canada

Sir Mortimer B. Davis - Jewish Genl

Montreal, Quebec, Canada

Local Institution - 176

Sherbrooke, Quebec, Canada

IC La Serena Research

La Serena, Coquimbo Region, Chile

Local Institution - 192

Las Condes, Metropolitana de Santiago, Chile

Local Institution - 193

Santiago, , Chile

Nanfang Hospital of Southern Medical University

Guangzhou, GD, China

The First Affiliated Hospital of Nanyang Medical College

Nanyang, Henan, China

Xiangya Hospital Central-South University

Changsha, Hunan, China

Local Institution - 804

Nanjing, Jiangsu, China

Local Institution - 818

Nantong, Jiangsu, China

Local Institution - 820

Nanchang, Jiangxi, China

Nanchang University - The Second Affiliated Hospital

Nanchang, Jiangxi, China

Local Institution - 821

Qingdao, Shandong, China

Local Institution - 816

Taiyuan, Shanxi, China

The Second Affiliated Hospital Of Kunming Medical University

Kunming, Yunnan, China

Beijing Peking Union Medical College Hospital

Beijing, , China

Local Institution - 802

Changchun, , China

Guangdong General Hospital

Guangzhou, , China

The First Affiliated Hospital Of Harbin Medical University

Harbin, , China

Local Institution - 809

Shanghai, , China

Local Institution - 801

Shanghai, , China

Local Institution - 811

Suzhou, , China

Local Institution - 800

Tianjin, , China

Tianjin Medical University General Hospital

Tianjin, , China

Local Institution - 810

Zhengzhou, , China

Local Institution - 161

Medellín, Antioquia, Colombia

Local Institution - 163

Bogotá, Distrito Capital de Bogotai, Colombia

Local Institution - 162

Floridablanca, Soto, Colombia

Local Institution - 341

Prague, , Czechia

Local Institution - 331

Angers, , France

Local Institution - 333

Clermont-Ferrand, , France

Local Institution - 324

Créteil, , France

Chu De Grenoble

Grenoble, , France

Local Institution - 327

Lille, , France

Local Institution - 332

Lyon, , France

CHU de Nice Archet I

Nice, , France

Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau

Nîmes, , France

Hopital Saint Louis

Paris, , France

Groupe Hospitalier Sud Hopital Haut Leveque USN

Pessac, , France

CHU La Miletrie

Poitiers, , France

ICANS Institut de cancerologie Strasbourg Europe

Strasbourg, , France

Local Institution - 330

Toulouse, , France

Unviversitatsklinikum Aachen

Aachen, , Germany

Stauferklinikum Schwab. Gmund

Baden-Warttemberg, , Germany

Local Institution - 299

Düsseldorf, , Germany

Universitatsklinikum Halle Saale

Halle, , Germany

Local Institution - 300

Hamburg, , Germany

Universitaetsklinikum Jena

Jena, , Germany

Local Institution - 297

Leipzig, , Germany

Local Institution - 301

Mannheim, , Germany

Johannes Wiesling Klinikum Minden

Minden, , Germany

Local Institution - 387

Pátrai, Achaia, Greece

Local Institution - 383

Alexandroupoli, , Greece

Evangelismos General Hospital of Athens

Athens, , Greece

Local Institution - 386

Athens, , Greece

Attikon University General Hospital

Athens, , Greece

University General Hospital of Patras

Rio Patras, , Greece

Georgios Papanikolaou General Hospital of Thessaloniki

Thessaloniki, , Greece

Local Institution - 661

Hong Kong, , Hong Kong

Prince of Wales Hospital the Chinese University of Hong Kong

Shatin, , Hong Kong

Local Institution - 462

Budapest, , Hungary

Local Institution - 463

Győr, , Hungary

Cork University Hospital

Cork, , Ireland

Mater Misercordiae Hospital

Dublin, , Ireland

St James Hospital

Dublin, , Ireland

Tel-Aviv Sourasky Medical Center

Tel Aviv, Tel Aviv, Israel

Rambam Medical Center

Haifa, , Israel

Hadassah Medical Organization

Jerusalem, , Israel

Meir Medical Center

Kfar Saba, , Israel

Shamir Medical Center - Assaf Harofeh

Ẕerifin, , Israel

IRCCS - Istituto Romagnolo per lo Studio Dei Tumori "Dino Amadori" (IRST)

Meldola (fc), Fc, Italy

Local Institution - 250

Ancona, , Italy

Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi

Bologna, , Italy

Asst Spedali Civili Di Brescia

Brescia, , Italy

Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico

Catania, , Italy

Azienda Ospedaliera Universitaria Careggi

Florence, , Italy

Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico

Milan, , Italy

Local Institution - 246

Napoli Campania, , Italy

A.O.U. Maggiore della Carit

Novara, , Italy

Azienda Ospedaliera Di Padova

Padua, , Italy

Local Institution - 248

Pisa, , Italy

Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli

Reggio Calabria, , Italy

Azienda Policlinico Universitario Umberto I

Roma, , Italy

Local Institution - 251

Roma, , Italy

Local Institution - 249

Roma, , Italy

Local Institution - 245

Terni, , Italy

Local Institution - 259

Torino, , Italy

Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese

Varese, , Italy

Centro Ricerche Cliniche di Verona S.r.l.

Verona, , Italy

The Japanese Red Cross Nagasaki Genbaku Hospital

Nagasaki, Nagasaki, Japan

Kindai University Hospital- Osakasayama Campus

Sayama, Osaka, Japan

Local Institution - 701

Bunkyo-ku, Tokyo, Japan

Local Institution - 709

Chūō, Yamanashi, Japan

Aomori Prefectural Central Hospital

Aomori, , Japan

Local Institution - 713

Bunkyō City, , Japan

Tokai University Hospital

Isehara City, Kanagawa, , Japan

Local Institution - 717

Kamakura, , Japan

Kameda General Hospital

Kamogawa, , Japan

Local Institution - 706

Maebashi, , Japan

University of Miyazaki Hospital

Miyazaki, , Japan

Osaka Metropolitan university Hospital

Osaka, , Japan

Ogaki Municipal Hospital

Ōgaki, , Japan

Local Institution - 708

Sapporo, , Japan

NTT Medical Center Tokyo

Shinagawa-ku, Tokyo, , Japan

Tokyo Women's Medical University Hospital

Shinjuku, , Japan

Local Institution - 710

Shinjyuku-ku, , Japan

Toyohashi Municipal Hospital

Toyohashi, , Japan

Local Institution - 551

Saida, South, Lebanon

Local Institution - 550

Badaro Beirut, , Lebanon

Local Institution - 552

Beirut, , Lebanon

Local Institution - 436

Gdansk, , Poland

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

Krakow, , Poland

Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Lodzi

Lodz, , Poland

Local Institution - 433

Poznan, , Poland

Specjalistyczny Szpital im. dra Alfreda Sokolowskiego

Wałbrzych, , Poland

Local Institution - 435

Wroclaw, , Poland

Local Institution - 395

Craiova, Dolj, Romania

Onco Card SRL

Brasov, , Romania

Local Institution - 391

Bucharest, , Romania

Prof. Dr. I. Chiricuta Institute of Oncology

Cluj-Napoca, , Romania

Local Institution - 500

Moscow, , Russia

Local Institution - 503

Saint Petersburg, , Russia

Local Institution - 502

Saint Petersburg, , Russia

Kyungpook National University Hospital

Daegu, , South Korea

Chonnam National University Hwasun Hospital

Hwasun-Gun, , South Korea

Local Institution - 643

Seongnam-si, , South Korea

Local Institution - 647

Seoul, , South Korea

The Catholic University of Korea Seoul - Saint Mary's Hospital

Seoul, , South Korea

Seoul National University Hospital

Seoul, , South Korea

Asan Medical Center

Seoul, , South Korea

Hospital Clinic de Barcelona

Barcelona, , Spain

Hospital Universitari Germans Trias i Pujol ICO Badalona

Barcelona, , Spain

Local Institution - 208

Granada, , Spain

Hospital Universitario De Gran Canaria Dr. Negrin

Las Palmas de Gran Canaria, , Spain

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Hospital Universitario 12 De Octubre

Madrid, , Spain

Local Institution - 202

Palma de Mallorca, , Spain

Universitario de Salamanca - Hospital Clinico

Salamanca, , Spain

Complejo Hospitalario Universitario De Santiago

Santiago de Compostela, , Spain

Hospital Universitario Virgen del Rocio

Seville, , Spain

Hospital Clinico Universitario De Valencia

Valencia, , Spain

Nottingham City Hospital

Nottingham, Nottinghamshire, United Kingdom

Heart of England NHS Foundation Trust

Birmingham, , United Kingdom

United Lincolnshire Hospitals NHS Trust

Boston, , United Kingdom

Churchhill Hospital

Oxford, , United Kingdom

Countries

United States; Argentina; Australia; Austria; Belgium; Canada; Chile; China; Colombia; Czechia; France; Germany; Greece; Hong Kong; Hungary; Ireland; Israel; Italy; Japan; Lebanon; Poland; Romania; Russia; South Korea; Spain; United Kingdom

Related Links

https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

BMS Clinical Trial Information

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT04717414.html

BMS Clinical Trial Patient Recruiting

Other Identifiers

2020-000607-36

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1260-9595

Identifier Type: REGISTRY

Identifier Source: secondary_id

ACE-536-MF-002

Identifier Type: -

Identifier Source: org_study_id